{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:08:51Z","timestamp":1770840531764,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05541-1","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:04:43Z","timestamp":1768795483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"1","key":"5541_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-025-02670-3","volume":"24","author":"Y Li","year":"2025","unstructured":"Li Y, Li D, Lin J, Zhou L, Yang W, Yin X, et al. Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease. Cardiovasc Diabetol. 2025;24(1):120.","journal-title":"Cardiovasc Diabetol"},{"issue":"31","key":"5541_CR2","first-page":"e947409","volume":"15","author":"MM Farahani","year":"2025","unstructured":"Farahani MM, Ghiasi SM, Karamali M, Vafa RG. Evaluating cardiovascular risk factors among healthcare professionals in Iran. Med Sci Monit. 2025;15(31):e947409.","journal-title":"Med Sci Monit."},{"issue":"1","key":"5541_CR3","doi-asserted-by":"publisher","first-page":"e20240870","DOI":"10.1590\/1806-9282.20240870","volume":"71","author":"L Li","year":"2025","unstructured":"Li L, Xu L. Association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus and evaluation of statin treatment effects. Rev Assoc Med Bras (1992). 2025;71(1):e20240870.","journal-title":"Rev Assoc Med Bras (1992)."},{"issue":"1","key":"5541_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","volume":"17","author":"V Ormazabal","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu\u00f1iga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.","journal-title":"Cardiovasc Diabetol."},{"issue":"13","key":"5541_CR5","doi-asserted-by":"publisher","first-page":"978745","DOI":"10.3389\/fendo.2022.978745","volume":"25","author":"D Wei","year":"2022","unstructured":"Wei D, Marrachelli VG, Melgarejo JD, et al. Lipoprotein profiles of fat distribution and its association with insulin sensitivity. Front Endocrinol (Lausanne). 2022;25(13):978745.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"5541_CR6","doi-asserted-by":"publisher","first-page":"e70206","DOI":"10.1002\/hsr2.70206","volume":"8","author":"AF Zaihan","year":"2025","unstructured":"Zaihan AF, Ahmad Hisham S, Ali Nasiruddin AY, Kow CS, Hasan SS, Ramachandram DS. Statin utilization for primary prevention of cardiovascular disease in patients developing first ST-segment elevation myocardial infarction: a Malaysian retrospective cohort study. Health Sci Rep. 2025;8(3):e70206.","journal-title":"Health Sci Rep."},{"issue":"2","key":"5541_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0319030","volume":"20","author":"PDWD De Zoysa","year":"2025","unstructured":"De Zoysa PDWD, Weerarathna TP, Darshana ILAN, et al. Statin use and low-density lipoprotein cholesterol target achievement for primary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus: a multicenter cross-sectional study in Sri Lanka. PLoS One. 2025;20(2):e0319030.","journal-title":"PLoS One"},{"issue":"2","key":"5541_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40199-024-00534-x","volume":"32","author":"M Kargar","year":"2024","unstructured":"Kargar M, Zare N, Jafarzadeh Kohneloo A, et al. Lipid management strategies for diabetic patients align with an evidence-based guideline. Daru. 2024;32(2):665\u201373.","journal-title":"Daru"},{"issue":"1","key":"5541_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11883-024-01248-w","volume":"27","author":"E Olmastroni","year":"2024","unstructured":"Olmastroni E, Scotti S, Galimberti F, Xie S, Casula M. Ezetimibe: Integrating established use with new evidence - a comprehensive review. Curr Atheroscler Rep. 2024;27(1):10.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"5541_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-025-01280-4","volume":"27","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ. Achieving more optimal lipid control with non-statin lipid lowering therapy. Curr Atheroscler Rep. 2025;27(1):32.","journal-title":"Curr Atheroscler Rep."},{"issue":"11","key":"5541_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310696","volume":"19","author":"L Liu","year":"2024","unstructured":"Liu L, Deng Y, Li L, Yang X, Yin Z, Lai Y. Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: a meta-analysis. PLoS One. 2024;19(11):e0310696.","journal-title":"PLoS One"},{"key":"5541_CR12","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.3390\/ijms21134725","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Jebari S, Larrea-Sebal A, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci. 2020;21:4725.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5541_CR13","doi-asserted-by":"publisher","first-page":"e00315","DOI":"10.1097\/XCE.0000000000000315","volume":"13","author":"A Goyal","year":"2024","unstructured":"Goyal A, Tariq MD, Jain H, et al. Efficacy and safety of double-dose statin monotherapy versus moderate-intensity statin combined with ezetimibe dual therapy in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Cardiovasc Endocrinol Metab. 2024;13(4):e00315.","journal-title":"Cardiovasc Endocrinol Metab."},{"issue":"2","key":"5541_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3803\/EnM.2018.33.2.219","volume":"33","author":"N Hong","year":"2018","unstructured":"Hong N, Lee YH, Tsujita K, et al. Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: a meta-analysis. Endocrinol Metab (Seoul). 2018;33(2):219\u201327.","journal-title":"Endocrinol Metab (Seoul)."},{"issue":"2","key":"5541_CR15","doi-asserted-by":"publisher","first-page":"103201","DOI":"10.1016\/j.dsx.2025.103201","volume":"19","author":"VH Schmitt","year":"2025","unstructured":"Schmitt VH, Hobohm L, Hahad O, et al. Impact of type 1 diabetes mellitus on mortality rate and outcome of hospitalized patients with myocardial infarction. Diabetes Metab Syndr. 2025;19(2):103201.","journal-title":"Diabetes Metab Syndr."},{"issue":"9","key":"5541_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"343","key":"5541_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.","journal-title":"BMJ."},{"issue":"9","key":"5541_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1475-2840-9-20","volume":"21","author":"G Bardini","year":"2010","unstructured":"Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010;21(9):20.","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"5541_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1463-1326.2009.01152.x","volume":"12","author":"S Conard","year":"2010","unstructured":"Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010;12(3):210\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"5541_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5551\/jat.54726","volume":"28","author":"K Fujisue","year":"2021","unstructured":"Fujisue K, Yamanaga K, Nagamatsu S, et al. Effects of statin plus ezetimibe on coronary plaques in acute coronary syndrome patients with diabetes mellitus: sub-analysis of PRECISE-IVUS trial. J Atheroscler Thromb. 2021;28(2):181\u201393.","journal-title":"J Atheroscler Thromb"},{"issue":"15","key":"5541_CR21","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382.","journal-title":"Circulation."},{"issue":"23","key":"5541_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033907","volume":"102","author":"Hu Wei-Syun","year":"2023","unstructured":"Wei-Syun Hu, Teng-Shun Yu, Lin C-L. Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke. Medicine (Baltimore). 2023;102(23):e33907.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"5541_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1248\/cpb.c18-00685","volume":"67","author":"Z Huang","year":"2019","unstructured":"Huang Z, Li Q, Ye W, Zhang Q, Li X. Efficacy and safety of ezetimibe in combination with atorvastatin for acute coronary syndrome patients accompanied with type 2 diabetes: a single-center, Non-randomized Cohort Study. Chem Pharm Bull (Tokyo). 2019;67(5):419\u201325.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"1","key":"5541_CR24","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1038\/s41598-021-86090-9","volume":"11","author":"Y-C Kao","year":"2021","unstructured":"Kao Y-C, Chen T-H, Liu C-H, et al. Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. Sci Rep. 2021;11(1):6697.","journal-title":"Sci Rep"},{"issue":"11","key":"5541_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","volume":"44","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023;44(11):972\u201383.","journal-title":"Eur Heart J."},{"issue":"14","key":"5541_CR26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12944-015-0004-7","volume":"18","author":"L Li","year":"2015","unstructured":"Li L, Zhang M, Fuxiang Su, et al. Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes. Lipids Health Dis. 2015;18(14):10.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"5541_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4093\/dmj.2023.0171","volume":"47","author":"JS Moon","year":"2023","unstructured":"Moon JS, Park IR II, Kim SS, et al. The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes mellitus: a randomized, multicenter, open, parallel, phase 4 study. Diabetes Metab J. 2023;47(6):818\u201325.","journal-title":"Diabetes Metab J."},{"issue":"3","key":"5541_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1479164112465212","volume":"10","author":"JB Rosen","year":"2013","unstructured":"Rosen JB, Jimenez JG, Pirags V, et al. A comparison of efficacy and safety of an ezetimibe\/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab Vasc Dis Res. 2013;10(3):277\u201386.","journal-title":"Diab Vasc Dis Res."},{"issue":"5","key":"5541_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.23736\/S0392-9590.17.03818-4","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang J, Ai X-B, Wang F, Zou Y-W, Li Li, Yi X-L. Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol. 2017;36(5):467\u201373.","journal-title":"Int Angiol"},{"issue":"372","key":"5541_CR30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.","journal-title":"BMJ."},{"issue":"8","key":"5541_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24334","volume":"47","author":"H Soleimani","year":"2024","unstructured":"Soleimani H, Mousavi A, Shojaei S, et al. Safety and effectiveness of high-intensity statins versus low\/moderate-intensity statins plus ezetimibe in patients with atherosclerotic cardiovascular disease for reaching LDL-C goals: a systematic review and meta-analysis. Clin Cardiol. 2024;47(8):e24334.","journal-title":"Clin Cardiol"},{"issue":"25","key":"5541_CR32","first-page":"00075","volume":"S0025\u20136196","author":"M Banach","year":"2025","unstructured":"Banach M, Jaiswal V, Ang SP, et al. Impact of lipid-lowering combination therapy with statins and ezetimibe vs statin monotherapy on the reduction of cardiovascular outcomes: a meta-analysis. Mayo Clin Proc. 2025;S0025\u20136196(25):00075\u20138.","journal-title":"Mayo Clin Proc."},{"issue":"1","key":"5541_CR33","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/s41598-025-00298-7","volume":"15","author":"HI Choi","year":"2025","unstructured":"Choi HI, Oh SJ, Jo YH, et al. Comparison of rosuvastatin 10 mg plus ezetimibe versus rosuvastatin 20 mg in atherosclerotic cardiovascular disease and type 2 diabetes. Sci Rep. 2025;15(1):16012.","journal-title":"Sci Rep."},{"issue":"25","key":"5541_CR34","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med."},{"issue":"1","key":"5541_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12933-024-02498-3","volume":"23","author":"EH Choo","year":"2024","unstructured":"Choo EH, Moon D, Choi IJ, et al. Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention. Cardiovasc Diabetol. 2024;23(1):396.","journal-title":"Cardiovasc Diabetol."},{"issue":"2","key":"5541_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1620\/tjem.2024.J019","volume":"263","author":"P-S Chen","year":"2024","unstructured":"Chen P-S, Lin J-L, Lin H-W, Lin S-H, Li Y-H. Risk of hemorrhagic stroke among patients treated with high-intensity statins versus pitavastatin-ezetimibe: a population based study. Tohoku J Exp Med. 2024;263(2):105\u201313.","journal-title":"Tohoku J Exp Med"},{"key":"5541_CR37","doi-asserted-by":"publisher","unstructured":"Sohn M, Park YH, Lim S. Comparative efficacy of initial statin and ezetimibe combination versus statin monotherapy on cardiovascular outcomes in diabetes mellitus: a nationwide cohort study. Diabetes Metab J. 2025. https:\/\/doi.org\/10.4093\/dmj.2024.0482.","DOI":"10.4093\/dmj.2024.0482"},{"issue":"6","key":"5541_CR38","first-page":"e61526","volume":"16","author":"SK Dadzie","year":"2024","unstructured":"Dadzie SK, Tabowei G, Kaur M, et al. A comparison of rosuvastatin monotherapy and rosuvastatin plus ezetimibe combination therapy in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Cureus. 2024;16(6):e61526.","journal-title":"Cureus."},{"key":"5541_CR39","doi-asserted-by":"publisher","unstructured":"Ramirez-Hernandez D, Lezama-Martinez D, Velazco-Bejarano B, et al. The beneficial effects of swimming training preconditioning on reducing vascular reactivity in chronic myocardial infarction: Independent of NO production. J Renin Angiotensin Aldosterone Syst. 2024;25.https:\/\/doi.org\/10.1177\/14703203241294029.","DOI":"10.1177\/14703203241294029"},{"key":"5541_CR40","doi-asserted-by":"publisher","unstructured":"Li M, Qu S, Xu X, et al. SerpinB1 promotes cardiomyocyte proliferation and heart regeneration via inhibiting ERBB2 degradation. J Renin Angiotensin Aldosterone Syst. 2025;26.https:\/\/doi.org\/10.1177\/14703203251403992.","DOI":"10.1177\/14703203251403992"},{"key":"5541_CR41","doi-asserted-by":"publisher","unstructured":"Inhibition of Th17 cell differentiation by aerobic exercise improves vasodilatation in diabetic mice. Clin Exp Hypertens. 46(1). https:\/\/doi.org\/10.1080\/10641963.2024.2373467.","DOI":"10.1080\/10641963.2024.2373467"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05541-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:14:08Z","timestamp":1770837248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05541-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5541"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05541-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not applicable for this systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}